Outcome-blind learner report. The evidence boundary is May 2, 2016 at 23:59:59 UTC, and the simulated decision time is May 3, 2016 at 13:30 UTC. Nothing that became public after the boundary is used to judge the decision.
Decision frame
This is a simulated long-only public-equity committee decision, not a reconstruction of an Intel board or management decision. The committee must decide whether to initiate or add exposure and how to govern re-underwriting of any existing holding. It has no authority to change Intel's operations or execute a security transaction.
Four alternatives are considered: add exposure, maintain without new gates, defer and re-underwrite, or ask an authorized human committee to review a reduction. The record does not disclose the simulated portfolio's current exposure, mandate, tax and liquidity constraints, or risk budget. A reduction, target price, or position size is therefore outside the evidence boundary. [claim.intel.cutoff.valuation-abstention; judgment.intel.cutoff.valuation-abstention]
Integrated-manufacturing hypothesis and roadmap conflict
Intel said that owning its manufacturing facilities could optimize performance, shorten time to market, and scale new products more rapidly. It also reported that a substantial majority of its microprocessors used its 14nm, 22nm, and 32nm processes at the end of FY2015. source · intel.cutoff.fy2015-10k
The same filing described a longer period of use for 14nm and 10nm, a yearly product introduction cadence, and Kaby Lake as a third 14nm product. That is an issuer roadmap claim, not proof of future yield, performance, reliability, customer qualification, volume, or economics. [evidence.intel.cutoff.kaby-lake-10nm-claim; claim.intel.cutoff.process-cadence-claim]
A contemporaneous Ars Technica report recorded Intel's confirmation that 10nm had moved to the second half of 2017 and that Kaby Lake would extend the 14nm sequence. The publisher bytes acquired for this case disclose a later modification timestamp, so the article is used only to corroborate the contemporaneously reported schedule change; it is not evidence of subsequent execution. source · ars.cutoff.intel-kaby-lake-2015
Intel itself warned that process transitions could suffer development and production delays, lower yields, defects, disrupted ramps, and higher costs. It also described manufacturing, facilities, equipment, R&D, and skilled labor as high fixed or hard-to-reduce costs, with underutilization, excess-capacity charges, accelerated depreciation, and write-down risk when demand disappoints. source · intel.cutoff.fy2015-10k
This is the central unresolved conflict: integration may create control and speed, but process misses can combine technical risk with operating leverage. The selected record has no matched product-level yield, schedule, customer-acceptance, wafer-cost, or return-on-manufacturing-capital test. [conflict.intel.cutoff.manufacturing-advantage-versus-execution; assumption.intel.cutoff.roadmap-execution]
Reported financial capacity
For FY2015 Intel reported revenue of $55.355 billion, gross profit of $34.679 billion, operating income of $14.002 billion, net income of $11.420 billion, operating cash flow of $19.017 billion, and $7.326 billion of cash additions to property, plant, and equipment. source · intel.cutoff.fy2015-10k
For Q1 2016 Intel reported revenue of $13.702 billion, gross profit of $8.130 billion, operating income of $2.568 billion, net income of $2.046 billion, operating cash flow of $4.055 billion, and $1.346 billion of cash additions to property, plant, and equipment. The quarter contained 14 weeks, so an unadjusted year-on-year comparison is not a like-for-like run rate. source · intel.cutoff.q1-2016-10q
The calculation ledger derives descriptive reported margins, changes, ratios, and cash-capital residuals from cited facts. Those checks are arithmetic, not forecasts. Operating cash flow minus cash property-and-equipment additions is not labeled free cash flow because maintenance capital, working-capital normalization, and required roadmap investment are unavailable. The model is transparent but non-authoritative without a frozen registry validation receipt. [table.intel.cutoff.deterministic-checks; judgment.intel.cutoff.valuation-abstention]
Segment evidence: positive and negative signals
In Q1 2016 Intel reported CCG revenue of $7.549 billion and operating income of $1.885 billion, versus $7.420 billion and $1.411 billion in the Q1 2015 comparison. It reported DCG revenue of $3.999 billion and operating income of $1.764 billion, versus $3.681 billion and $1.699 billion. source · intel.cutoff.q1-2016-10q
Intel's accompanying commentary described CCG revenue up 2% while platform volume fell 15%, including a 44% fall in tablet volume. It described DCG revenue up 9%, platform volume up 13%, and platform average selling price down 3%. The DCG evidence opposes a categorical negative view, while the CCG volume evidence opposes assuming that consolidated results demonstrate stable client demand. Week count, product mix, and contribution economics remain incomplete. source · intel.cutoff.q1-2016-cfo-commentary
PSG entered the reported segment perimeter after the Altera acquisition. Intel reported $359 million of Q1 PSG revenue and a $200 million operating loss, while explaining that deferred-revenue and acquired-inventory fair-value adjustments affected those figures. The GAAP segment results remain reported facts; the issuer's purchase-accounting explanation is not silently reversed into an adjusted profit. source · intel.cutoff.q1-2016-10q
Intel also attributed about one percentage point of the Q4-to-Q1 GAAP gross-margin bridge to higher factory startup costs, primarily on 10nm. The point attribution was approximate and is retained as an issuer claim, not an independently measured process cost. source · intel.cutoff.q1-2016-cfo-commentary
Altera, liquidity, and restructuring
Intel's preliminary Altera allocation recorded $14.451 billion of consideration net of acquired cash, including $5.433 billion of goodwill and $7.566 billion of identified intangibles. The allocation was not final. Those amounts do not establish strategic fit, realized synergy, or an acquisition return. source · intel.cutoff.q1-2016-10q
Intel said the transaction was funded in part by $9.5 billion of long-term debt issued in 2015 and $4.0 billion borrowed against its short-term facility in Q1 2016, with the remainder from commercial paper and existing cash and investments. At April 2, 2016, the company reported $15.091 billion of cash, short-term investments, and trading assets against $25.369 billion of short- and long-term debt. About $14.0 billion of the liquid-assets balance was held outside the United States, and approximately $953 million of that amount was available in the United States without incremental tax above amounts already accrued. [evidence.intel.cutoff.altera-financing; evidence.intel.cutoff.q1-liquidity-debt; evidence.intel.cutoff.foreign-cash; claim.intel.cutoff.altera-funding; claim.intel.cutoff.liquidity-debt]
Positive operating cash flow is therefore not equivalent to unrestricted funding resilience. The record lacks a complete maturity, covenant, facility, commercial-paper, working-capital, restructuring-cash, and roadmap-capital schedule. [conflict.intel.cutoff.cash-generation-versus-funding; assumption.intel.cutoff.funding-resilience]
Intel announced up to 12,000 position reductions, estimated $750 million of savings in 2016, a $1.4 billion annual run-rate saving by mid-2017, and an approximately $1.2 billion Q2 charge. These are announced actions and issuer estimates; neither the savings nor the cash timing is treated as realized at the cutoff. source · intel.cutoff.q1-2016-restructuring
Scenarios and six gates
The packet uses subjective three-year weights of 25% for roadmap recovery, 45% for an uneven transition, and 30% for execution and funding strain. They are organizing assumptions, not calibrated semiconductor-roadmap frequencies or valuation outputs. [assumption.intel.cutoff.scenario-weights]
Any renewed underwriting should apply six separate gates:
- Technical validation: approved definitions for yield, defect density, power, performance, reliability, qualification, and volume readiness.
- Roadmap execution: planned-versus-actual product and process milestones, including scope changes, qualification, launch, volume, and customer deployment.
- Segment economics: stable CCG, DCG, and PSG units, ASP, mix, contribution, and purchase-accounting bridges.
- Manufacturing/capital: yield and utilization tied to startup cost, depreciation, inventory, cash investment, required reinvestment, and downside returns.
- Funding resilience: stressed sources and uses after debt, geographic cash constraints, covenants, restructuring, working capital, and roadmap commitments.
- Valuation readiness: verified cutoff price, diluted capitalization, approved forecast and capital policy, intrinsic-value range, mandate, current exposure, and risk budget.
These gates keep evidence confidence, underwriting readiness, business quality, and price attractiveness separate. Passing one cannot substitute for another. [judgment.intel.cutoff.six-gate-framework]
Recommendation
Choose defer and re-underwrite. Initiate no new exposure and add no capital on this record. Route any existing holding to an authorized human committee as the six gates and missing inputs are resolved. This recommendation does not size or execute a trade. [judgment.intel.cutoff.defer-and-reunderwrite]
Confidence is moderate. Manufacturing scale, positive cash generation, DCG growth, and restructuring optionality are genuine opposing evidence. The reported process delay, process-transition risk, CCG volume pressure, 10nm startup cost, Altera-funded leverage, geographic cash constraints, and incomplete valuation inputs prevent those strengths from supporting an add. Neither branch establishes permanent impairment or durable recovery.
Reconsider initiating or adding only after all six gates pass on matched evidence and a human-approved valuation and portfolio package is complete. Escalate a failed gate for human re-underwriting; do not convert it into an automated buy, hold, reduce, or sell instruction. Abstain from target price and position size until the unknown rows in the underwriting table are resolved. [table.intel.cutoff.underwriting-abstentions; claim.intel.cutoff.valuation-abstention]
Material limitations
- No independent 10nm engineering, customer-qualification, yield, or volume evidence is in the cutoff record.
- Product-level share, mix, unit contribution, wafer cost, utilization, maintenance capital, and return on manufacturing capital are incomplete.
- The Altera allocation is preliminary; complete integration cost, synergy, organic contribution, and acquisition-return schedules are unavailable.
- No calibrated roadmap reference class, complete downside funding model, or approved forecast is supplied.
- No verified cutoff market-price and diluted-capitalization bridge or portfolio authority package supports valuation, sizing, or execution.
- The report makes no allegation of misconduct and provides no personalized investment, accounting, tax, or legal advice.